KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to -$847.8 million.

  • Royalty Pharma's Cash from Investing Activities fell 6768.61% to -$847.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.6 billion, marking a year-over-year increase of 3972.7%. This contributed to the annual value of -$1.6 billion for FY2025, which is 3972.7% up from last year.
  • As of Q4 2025, Royalty Pharma's Cash from Investing Activities stood at -$847.8 million, which was down 6768.61% from -$958.3 million recorded in Q3 2025.
  • Royalty Pharma's Cash from Investing Activities' 5-year high stood at $503.9 million during Q1 2025, with a 5-year trough of -$1.4 billion in Q3 2022.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$528.6 million (2021), whereas its average is -$463.2 million.
  • Per our database at Business Quant, Royalty Pharma's Cash from Investing Activities plummeted by 510247.2% in 2023 and then skyrocketed by 68155.45% in 2025.
  • Quarter analysis of 5 years shows Royalty Pharma's Cash from Investing Activities stood at -$551.6 million in 2021, then surged by 175.18% to $414.7 million in 2022, then crashed by 341.16% to -$1.0 billion in 2023, then soared by 49.45% to -$505.6 million in 2024, then plummeted by 67.69% to -$847.8 million in 2025.
  • Its Cash from Investing Activities was -$847.8 million in Q4 2025, compared to -$958.3 million in Q3 2025 and -$312.0 million in Q2 2025.